# US 8,772,264 B2 · Methods of treating hematologic cancers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,772,264 B2
- Document ID: US8772264B2
- Status: Granted
- Kind: B2
- Application number: 13/388,751
- Filed: 2010-07-27
- Published: 2012-07-26
- Granted: 2014-07-08
- Earliest claimed: 2009-08-04
- Assignees: Mayo Foundation for Medical Education and Research
- Applicants: Neil E. Kay; Tait D. Shanafelt
- Inventors: Neil E. Kay; Tait D. Shanafelt
- Web page: https://patentgrep.com/patent/US8772264B2

## CPC

- A61K 31/7076: containing purines, e.g. adenosine, adenylic acid
- A61K 31/196: the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
- A61K 31/353: 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K 31/4164: 1,3-Diazoles
- A61K 31/52: Purines, e.g. adenine
- A61K 31/56: Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This disclosure relates to the treatment of hematologic cancers, for example, cancers of the blood, by methods that include administration of EGCG and at least one of a purine nucleoside analog and an alkylating agent. In particular, methods of treating chronic lymphocytic leukemia (CLL) and acute lymphocytic leukemia (ALL) are described.

## Claims

### Claim 1

A method of treating a hematologic cancer in a subject having a hematologic cancer comprising the steps of:
(a) administering to the subject an effective amount of epigallocatechin gallate (EGCG), or a pharmaceutically acceptable salt, ester, or salt of an ester thereof; and
(b) administering to the subject an effective amount of fludarabine, or a pharmaceutically acceptable salt, ester, or salt of an ester thereof, and chlorambucil, or a pharmaceutically acceptable salt, ester, or salt of an ester thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the EGCG, fludarabine, and chlorambucil are admixed prior to administration.

### Claim 3 (depends on 1)

The method of claim 1, wherein the EGCG and the chlorambucil are admixed prior to administration.

### Claim 4 (depends on 1)

The method of claim 1, wherein the EGCG and the fludarabine are admixed prior to administration.

### Claim 5 (depends on 1)

The method of claim 1, wherein the EGCG and at least one of the fludarabine and the chlorambucil are administered concurrently.

### Claim 6 (depends on 1)

The method of claim 1, wherein the fludarabine and the chlorambucil are admixed prior to administration.

### Claim 7 (depends on 1)

The method of claim 1, wherein the EGCG and at least one of the fludarabine and the chlorambucil are administered sequentially.

### Claim 8 (depends on 1)

The method of claim 1, wherein the hematologic cancer is chosen from chronic lymphocytic leukemia and acute lymphoblastic leukemia.

### Claim 9

A method of treating chronic lymphocytic leukemia in a subject having a hematologic cancer, the method comprising administering to the subject a composition comprising EGCG, or a pharmaceutically acceptable salt, ester, or salt of an ester thereof, flurdarabine, or a pharmaceutically acceptable salt, ester, or salt of an ester thereof, and chlorambucil, or a pharmaceutically acceptable salt, ester, or salt of an ester thereof.